
CNS Brainstorm Episode 48 "Pediatric NF1 Therapeutics" with guest Bonnie Kaur, MD
Child Neurology Society's Brainstorm
00:00
Who is eligible for MEK inhibitors
Bonnie Kaur summarizes FDA approvals: treat any patient >1 year (selumetinib) or >2 years (mirdametinib) with inoperable symptomatic plexiform NF.
Play episode from 03:10
Transcript


